## Stephanie Galanie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/340840/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Complete biosynthesis of opioids in yeast. Science, 2015, 349, 1095-1100.	12.6	809
2	A microbial biomanufacturing platform for natural and semisynthetic opioids. Nature Chemical Biology, 2014, 10, 837-844.	8.0	231
3	Malleability of the SARS-CoV-2 3CL Mpro Active-Site Cavity Facilitates Binding of Clinical Antivirals. Structure, 2020, 28, 1313-1320.e3.	3.3	108
4	Mesoscale porous silica as drug delivery vehicles: Synthesis, characterization, and pH-sensitive release profiles. Microporous and Mesoporous Materials, 2011, 141, 128-134.	4.4	67
5	Engineering biosynthetic enzymes for industrial natural product synthesis. Natural Product Reports, 2020, 37, 1122-1143.	10.3	55
6	High-Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Noncovalent Inhibitor. Journal of Chemical Information and Modeling, 2022, 62, 116-128.	5.4	54
7	Optimization of yeast-based production of medicinal protoberberine alkaloids. Microbial Cell Factories, 2015, 14, 144.	4.0	51
8	Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease. Journal of Medicinal Chemistry, 2021, 64, 17366-17383.	6.4	32
9	Hit Expansion of a Noncovalent SARS-CoV-2 Main Protease Inhibitor. ACS Pharmacology and Translational Science, 2022, 5, 255-265.	4.9	17
10	Molecular tools for chemical biotechnology. Current Opinion in Biotechnology, 2013, 24, 1000-1009.	6.6	11